Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exagen Inc. - Common Stock
(NQ:
XGN
)
6.730
+0.280 (+4.34%)
Streaming Delayed Price
Updated: 10:50 AM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exagen Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
What Analysts Are Saying About Exagen Stock
↗
July 30, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 29, 2025
Via
Benzinga
Exagen Q2 Revenue Jumps 14 Percent
↗
July 29, 2025
Via
The Motley Fool
Topics
Intellectual Property
Exagen Inc (NASDAQ:XGN) Surpasses Revenue Estimates in Q2 2025 Despite Wider Loss, Shares Rally in Pre-Market Trading
↗
July 29, 2025
Exagen Inc (XGN) beats Q2 2025 revenue estimates with $17.2M but posts wider loss. Stock jumps 6.77% pre-market as investors focus on growth potential.
Via
Chartmill
Exagen Inc. Reports Strong Q2 2025 Results
July 29, 2025
From
Exagen Inc.
Via
GlobeNewswire
Earnings Scheduled For July 29, 2025
↗
July 29, 2025
Via
Benzinga
Earnings Scheduled For May 5, 2025
↗
May 05, 2025
Via
Benzinga
Exagen Inc. Appoints Chas McKhann to Board of Directors
July 17, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
July 15, 2025
From
Exagen Inc.
Via
GlobeNewswire
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
June 23, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
May 09, 2025
From
Exagen Inc.
Via
GlobeNewswire
Top movers in Thursday's pre-market session
↗
May 08, 2025
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
Exagen Inc. Prices Public Offering of Common Stock
May 08, 2025
From
Exagen Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 08, 2025
Via
Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
↗
May 07, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
May 07, 2025
Via
Benzinga
Exagen Inc. Announces Proposed Public Offering of Common Stock
May 07, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
May 05, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
April 28, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
April 21, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
March 11, 2025
From
Exagen Inc.
Via
GlobeNewswire
Earnings Scheduled For March 11, 2025
↗
March 11, 2025
Via
Benzinga
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
February 25, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Upcoming Investor Conferences
February 04, 2025
From
Exagen Inc.
Via
GlobeNewswire
Tuesday's session: top gainers and losers
↗
February 04, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
January 12, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
December 12, 2024
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
November 14, 2024
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 13, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024
From
Exagen Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
